Nature Reviews Gastroenterology & Hepatology

Article	Citations
Genetic factors in alcohol-related cirrhosis	1014
Microbial cues stimulate linear growth in undernourished mice	789
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	578
Regulating protease homeostasis in irritable bowel syndrome	465
Detecting gut osmolality changes to quench thirst	460
IVF in women with chronic liver disease or post-liver transplantation	405
Sugar intake during adolescence and risk of colorectal polyps	346
No beneficial effect of G-CSF in treating ACLF	289
Jumping the chasm from postdoc to PI	278
Showing a sensitive side	268
Understanding remodelling of bile ducts to promote polycystic liver disease	255
Inter-disciplinary collaboration for innovation in gastroenterology	250
The challenges facing female transplant hepatologists as young faculty	244
A Roadmap for the Human Gut Cell Atlas	234
Hippo signalling in the liver: role in development, regeneration and disease	232
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	228
Hybrid EASL Congress 2023	216
Microbiota-based biomarkers and therapeutics for cancer management	208
Neuropod cells — sensing a sweet spot in the gut	208
Rectally shed SARS-CoV-2 lacks infectivity: time to rethink faecal–oral transmission?	207
Pouchitis: pathophysiology and management	205
Hybrid APASL meeting 2024	199
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	197
Achieving health equity in liver disease pharmacotherapy	196
Striving to optimize colorectal cancer prevention	193

ZBTB46+ ILC3s promote intestinal health	191
Effect of bariatric surgery on risk of oesophagogastric cancer	191
A role for the gut microbiota in immune checkpoint inhibitor-induced colitis	179
Machine perfusion of the liver: applications in transplantation and beyond	173
Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases	169
Justice, equity, diversity and inclusion in gastroenterology and hepatology	163
Mapping neuroimmune interactions in the gut	160
Anti-SARS-CoV-2 vaccine in liver transplantation	151
Promoting allyship to support and uplift the LGBTQIA+ community	142
Rhythmicity of infant microbiota and dietary effects	135
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	133
Insight into virome development	124
Long-term normothermic liver perfusion	123
Intestinal organ chips for disease modelling and personalized medicine	121
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	119
Is less more? Challenging dogma for individualized fluid resuscitation	113
Zolbetuximab treatment in metastatic gastric cancer	113
Hepatitis D virus: more attention needed	111
Human hepatocyte organoids model early NAFLD	109
Comparing elimination diet therapies for eosinophilic oesophagitis	103
Long-term dynamic ex vivo organ preservation	102
Sphingolipids in hepatic metabolism	100
Examining the prevalence of NAFLD and NASH in a US cohort	99
Molecular landscape of NASH-HCC	95
2023 FDA approvals in gastroenterology and hepatology	92
A gut–liver axis in intestinal stem cell fitness	92
Contrasting aspects of human excreta	91
Disability inclusion in research and health care	90
Western lifestyle, metaflammation and the cell of origin of colon cancer	90
Metabolism of 5-ASA by the gut microbiome	89
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications	88
High-density lipoprotein lipidome: a neglected source of hepatic lipids	87
Alcohol-free and low-strength drinks: friend or foe?	86
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	85
Dietary and metabolic effects on intestinal stem cells in health and disease	85
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	82
Exploring liver cancer biology through functional genetic screens	81
Macrophages in intestinal homeostasis and inflammatory bowel disease	80
What are the clinical settings and outcomes of lean NAFLD?	79
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease	78
A serious side to social media	75
Fetal liver development and implications for liver disease pathogenesis	74
Nomenclature of HBV core protein-targeting antivirals	73
Re-examining chemically defined liquid diets through the lens of the microbiome	73
Current developments in gastric cancer: from molecular profiling to treatment strategy	72
Artificial intelligence and automation in endoscopy and surgery	70
Leveraging diet to engineer the gut microbiome	68
Single-cell RNA sequencing in pancreatic cancer	67
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease	66
Location is important: differentiation between ileal and colonic Crohn’s disease	65

Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	64
Author Correction: Current and future colorectal cancer screening strategies	62
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	58
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis	57
Author Correction: Improving IBD outcomes in the era of many treatment options	57
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	55
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease	54
Global epidemiology of cirrhosis — aetiology, trends and predictions	53
Vaccination at the forefront of the fight against hepatitis B and C	53
Medical images, social media and consent	51
Improving IBD outcomes in the era of many treatment options	50
Digestive Disease Week 2022	50
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	49
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	49
Metabolic health across the ages: how microbiota members support our well-being	48
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	48
Combination therapy with methotrexate in paediatric Crohn’s disease	46
Resmetirom safe for nonalcoholic fatty liver disease	45
Evidence-based alcohol policies are the answer	45
Elafibranor in primary biliary cholangitis	41
New target and timing in PDAC immunotherapy?	39
Promising results for exclusion diet in adults	38
Gut mycobiota modulates antifungal antibody-mediated immunity	36
Wound healing in the colon	36
Filgotinib for ulcerative colitis	34
Colonoscopy screening and risk of CRC	33
Gastric metaplasia could initiate the serrated neoplasia pathway in CRC	33
Discontinuation of infliximab in patients with Crohn’s disease on combination therapy	32
B cells in colonic mucosal healing	32
Hepatic IRF3 in glucose intolerance	32
Safety of in utero exposure to maternal IBD pharmacotherapies	31
Targeting PARG in HCC	31
Location, location, location — spatial insight into hepatic macrophage populations	28
Decoding therapy resistance in liver tumours: a giant leap	27
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	27
A pathway to therapy for HER2+ metastatic biliary tract cancer	27
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	26
GLP1-mediated gut–brain neural circuit controls appetite suppression	25
Envisioning how to advance the MASH field	25
GWAS reveals variants for alcohol-related hepatocellular carcinoma	25
Oral microbiome therapy efficacious for recurrent C. difficile infection	24
Treating SBS with organoids	23
Ozanimod is efficacious in ulcerative colitis	23
Promising phase I interim results for CAR T cells in gastrointestinal cancers	23
Liver fibrosis with methotrexate — an overestimated risk?	22
Lenvatinib plus EGFR inhibition for liver cancer	21
Cirrhosis-associated immune dysfunction	21
The global burden of coeliac disease: opportunities and challenges	21
EASL SLD Summit 2023	21
Advancing the global public health agenda for NAFLD: a consensus statement	21
Gut feelings: mechanosensing in the gastrointestinal tract	21
Deciphering potential implications of dietary microplastics for human health	20
New understanding of hepatobiliary MRI	20
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	19
Sex and ethnic disparities persist in hepatitis B management	19
Intermittent fasting for NASH and HCC in mice	18
Gut–brain axis key to fat preference	18
No excess cancer risk for non-erosive disease	18
Novel interventions against alcohol-related liver disease	18
A distinct CD103+Vγ4+ γδ T cell subset is linked to lesion healing and improved prognosis	18
Targeting hyperactive tRNA modification improves anti-PD1 efficacy	17
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	17
Digestive Disease Week 2023	17
A deep dive into the submerged ‘coeliac iceberg’	17
Understanding HCC sex disparities	17
Live bacterial therapeutics for detection and treatment of colorectal cancer	16
A crucial Fusobacterium nucleatum clade in colorectal cancer	16
Bacteriophages and their potential for treatment of gastrointestinal diseases	16
See the reality again in the field of liver transplantation	15
Metastatic pancreatic cancer and the liver	15
Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease	15
Unlocking the promise of RAS inhibition in pancreatic cancer	14
Incretin-based therapies for liver disease	14
Toripalimab and chemotherapy in oesophageal squamous cell carcinoma	14
The tumour-associated microbiome	14
Tango of B cells with T cells in the making of secretory antibodies to gut bacteria	13
IBD risk prediction using multi-ethnic polygenic risk scores	13
Standardized reporting of gastroenterology-related social media scholarship for career advancement	12
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation	12
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	12

Inflammatory bowel disease in pregnancy and breastfeeding	12
Mechanisms and pathophysiology of Barrett oesophagus	11
The maternal gut microbiome in pregnancy: implications for the developing immune system	11
The promise of the gut microbiome as part of individualized treatment strategies	11
Disease prevention trials in IBD: feasibility to future outlook	11
Combination therapies: the next major frontier in IBD management	11
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	11
Benign liver tumours: understanding molecular physiology to adapt clinical management	10
COVID-19 and liver disease: mechanistic and clinical perspectives	10
Environmental enteric dysfunction: gut and microbiota adaptation in pregnancy and infancy	10
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	10
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	9
Ammonia-induced stress response in liver disease progression and hepatic encephalopathy	9
Reply to ‘An expert panel Consensus Statement on ALD without experts by experience’	9
A resource for the food microbiome and its links with the human microbiome	9
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	9
Digital twins are integral to personalizing medicine and improving public health	9
The pancreatic cancer genome revisited	8
Food inequity and insecurity and MASLD: burden, challenges, and interventions	8
Advancing on pancreatic cancer	8
Bile acid transport inhibitors in paediatric hepatology: more than just an itch	8
The immune microenvironment in gastric adenocarcinoma	8
Etrasimod for ulcerative colitis: evaluating phase III results	8
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	8
Regulation and functional roles of chemokines in liver diseases	8
Author Correction: Reply to: Postbiotics — when simplification fails to clarify	7
Black voices in gastroenterology and hepatology	7
PDAC: advances in tumour microenvironment, microbiome and AI	7
Hybrid ILC 2022	7
Transport functions of intestinal lymphatic vessels	7
Positive phase III trials for ileal bile acid transporter inhibitors	7
Saliva — a new route for enteric viruses	6
Tackling sorbitol intolerance	6
Fungi in Crohn’s disease and mucosal healing	6
Cellular stress and TH17 cell induction in the gut	6
Gastrointestinal health and the environment: a bidirectional relationship	6
Expanding the catalogue of human gut bacteriophages	6
Siderophore cross-feeding between fungi and Salmonella	6
Medical therapy of paediatric inflammatory bowel disease	6
Biomarker shows no clinical use in guiding treatment for Crohn’s disease	6
Maralixibat relieves chronic cholestasis in children	5
A link to the past	5
Lanifibranor and NASH resolution	5
HDCA ameliorates NAFLD in mice	5
Upadacitinib therapy for Crohn’s disease	5
Role of intestinal B cells in NASH and liver fibrosis	5
Catheter drainage in necrotizing pancreatitis	5
Envisioning adalimumab for paediatric patients with ulcerative colitis	5
Lactylation and HCC progression	5
Therapeutic base editing in the adult liver	5
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	5
Phage therapy alleviates NAFLD in mice	5
Human liver tissue in a mouse host	5
Endogenous ethanol production in health and disease	5
Transglutaminase 2 inhibitor for coeliac disease	4
Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States	4
IL-17A-producing CD8+ T cells in pancreatic cancer	4
Post-surgical ctDNA in patients with CRC	4
Sugemalimab with chemotherapy for advanced ESCC	4
Unravelling the genetics of irritable bowel syndrome	4
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	4
Gastrointestinal post-acute COVID-19 syndrome	4
Ultra-processed diet increases CRC risk	4
Adalimumab biosimilar comparable to originator in patients with advanced Crohn’s disease	4
Human duodenal cells contribute to liver regeneration	4
Fatty pancreas associated with subsequent diabetes mellitus development	4
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	4
Characterizing the genomic landscape of colorectal cancer	4
C. difficile toxin strikes a nerve in the gut	4
From stem to stern: LGR5+ as a marker for intestinal crypts	4
Inflammation to cancer in PSC	4
Embracing many rainbows: the realities of being a gay physician, mother and patient	4
Development of MKK4 inhibitors for liver regeneration	4
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis	3
Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma	3
Therapeutic pipeline in nonalcoholic steatohepatitis	3
Understanding the physiology of human defaecation and disorders of continence and evacuation	3
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism	3
Nanoparticles in NAFLD therapeutics	3
Early detection of pancreatic cancer using DNA-based molecular approaches	3
Follow-up of SER-109 for recurrent C. difficile	3
Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury	3
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology	3
Intercrypt goblet cells — the key to colonic mucus barrier function	3
The metabolic nature of inflammatory bowel diseases	3
Gut-derived T cells might cause brain injury in NEC	3
Integrated systems approach to identify environmental factors in intestinal inflammation	3
Women in endoscopy: leading the way	3
CIDEB variants protect against liver disease	3
Break the taboo with poo	3
The microbiota and the gut–liver axis in primary sclerosing cholangitis	3
Amitriptyline as second-line treatment for IBS in primary care settings	3
Strengthening the foundation of African microbiome research: strategies for standardized data collection	2
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease	2
Mother-to-child transmission of hepatitis B: current status and the road forward	2